JIXING, founded and backed by RTW, is a clinical-stage biopharmaceutical company committed to bringing innovative medicines to Chinese patients with serious and life-threatening diseases. The collaboration will grant Bayer privileged rights to negotiate the commercialization of JIXING's pipeline assets in the areas of cardiovascular diseases and ophthalmology.
In addition to tapping into Bayer's deep experience in the cardiovascular and ophthalmology fields, the collaboration will leverage the company's significant presence in
'Collaborating with RTW is an important step in our ongoing efforts to transform patient care in areas of high unmet medical need,' said
'JIXING is on an exciting growth trajectory, driven by a world-class research and development team with a unique understanding of how to most effectively deliver innovative therapies that address complicated diseases to millions of Chinese patients,' said
'We are pleased to enter into this strategic partnership with Bayer, a leading multinational pharmaceutical company with a strong presence in
Leaps by Bayer, the impact investment arm of
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of
About JIXING
JIXING is a biopharmaceutical company headquartered in
JIXING's cardiovascular portfolio includes 3 assets in late-stage clinical development (aficamten, etripamil, omecamtiv mecarbil) and 1 in pre-clinical stage (JX09). JIXING's ophthalmology portfolio includes 4 assets in late-stage clinical development (varenicline solution nasal spray/US brand name TYRVAYA, OC-02 nasal spray, JX06/LNZ100, JX07/LNZ101) and 1 asset in pre-clinical stage (JX08).
About
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Contact:
Dr.
Tel: +49 214 60001275
Email: imke.meyer@bayer.com
Ji Xing
Email: media@jixingbio.com
Email: jjgb@rtwfunds.com
(C) 2024 Electronic News Publishing, source